F Puledda, EM Silva, K Suwanlaong, PJ Goadsby - Journal of Neurology, 2023 - Springer
Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas …
Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and …
R Messina, EM Huessler, F Puledda… - …, 2023 - journals.sagepub.com
Background Direct comparisons of the tolerability and safety of migraine preventive treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …
Background Several novel treatments targeting the calcitonin gene-related peptide pathway have been developed for migraine. We evaluated the efficacy of these medications …
LH Overeem, A Peikert, MD Hofacker, K Kamm… - …, 2022 - journals.sagepub.com
Background Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody …
F Vernieri, C Altamura, N Brunelli, CM Costa… - The journal of headache …, 2021 - Springer
Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness …
F Vandervorst, L Van Deun, A Van Dycke… - The journal of headache …, 2021 - Springer
Background Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not …
Objective While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety …
B Raffaelli, M Fitzek, LH Overeem, E Storch… - The Journal of …, 2023 - Springer
Background Clinical trials and real-world studies revealed a spectrum of response to CGRP (-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at …